Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

InMed Pharmaceuticals Inc.: Squadron Capital Management LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Squadron Capital Management LLC amended its Schedule 13G filing on InMed Pharmaceuticals Inc., updating its beneficial ownership stake with the SEC under accession number 0002050709-26-000034. The amendment signals a change in the investment firm's position in the clinical-stage biopharmaceutical company, which develops cannabinoid-based therapies. Schedule 13G filings are required of investors holding passive stakes above 5% in a public company, and amendments typically reflect shifts in ownership or intent. The specific size and direction of Squadron's revised stake were not detailed in the filing headline, leaving the exact percentage change unclear. Investors will watch for further 13G or 13D filings to gauge whether Squadron's position continues to evolve.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

InMed Pharmaceuticals Inc., Squadron Capital Management LLC